Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A phase 2, randomized, double-blind, placebo- controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: a Gynecologic Oncology Group partners study.
Monk BJ, Brady MF, Aghajanian C, Lankes HA, Rizack T, Leach J, Fowler JM, Higgins R, Hanjani P, Morgan M, Edwards R, Bradley W, Kolevska T, Foukas P, Swisher EM, Anderson KS, Gottardo R, Bryan JK, Newkirk M, Manjarrez KL, Mannel RS, Hershberg RM, Coukos G. Monk BJ, et al. Among authors: manjarrez kl. Ann Oncol. 2017 May 1;28(5):996-1004. doi: 10.1093/annonc/mdx049. Ann Oncol. 2017. PMID: 28453702 Free PMC article. Clinical Trial.
Integrative Development of a TLR8 Agonist for Ovarian Cancer Chemoimmunotherapy.
Monk BJ, Facciabene A, Brady WE, Aghajanian CA, Fracasso PM, Walker JL, Lankes HA, Manjarrez KL, Danet-Desnoyers GH, Bell-McGuinn KM, McCourt CK, Malykhin A, Hershberg RM, Coukos G. Monk BJ, et al. Among authors: manjarrez kl. Clin Cancer Res. 2017 Apr 15;23(8):1955-1966. doi: 10.1158/1078-0432.CCR-16-1453. Epub 2016 Oct 4. Clin Cancer Res. 2017. PMID: 27702821 Free PMC article. Clinical Trial.
Phase Ib Trial of the Toll-like Receptor 8 Agonist, Motolimod (VTX-2337), Combined with Cetuximab in Patients with Recurrent or Metastatic SCCHN.
Chow LQM, Morishima C, Eaton KD, Baik CS, Goulart BH, Anderson LN, Manjarrez KL, Dietsch GN, Bryan JK, Hershberg RM, Disis ML, Martins RG. Chow LQM, et al. Among authors: manjarrez kl. Clin Cancer Res. 2017 May 15;23(10):2442-2450. doi: 10.1158/1078-0432.CCR-16-1934. Epub 2016 Nov 3. Clin Cancer Res. 2017. PMID: 27810904 Clinical Trial.
Effect of Adding Motolimod to Standard Combination Chemotherapy and Cetuximab Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck: The Active8 Randomized Clinical Trial.
Ferris RL, Saba NF, Gitlitz BJ, Haddad R, Sukari A, Neupane P, Morris JC, Misiukiewicz K, Bauman JE, Fenton M, Jimeno A, Adkins DR, Schneider CJ, Sacco AG, Shirai K, Bowles DW, Gibson M, Nwizu T, Gottardo R, Manjarrez KL, Dietsch GN, Bryan JK, Hershberg RM, Cohen EEW. Ferris RL, et al. Among authors: manjarrez kl. JAMA Oncol. 2018 Nov 1;4(11):1583-1588. doi: 10.1001/jamaoncol.2018.1888. JAMA Oncol. 2018. PMID: 29931076 Free PMC article. Clinical Trial.
First-in-human study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of ALPN-101, a dual CD28/ICOS antagonist, in healthy adult subjects.
Yang J, Lickliter JD, Hillson JL, Means GD, Sanderson RJ, Carley K, Tercero A, Manjarrez KL, Wiley JR, Peng SL. Yang J, et al. Among authors: manjarrez kl. Clin Transl Sci. 2021 Jul;14(4):1314-1326. doi: 10.1111/cts.12983. Epub 2021 Mar 2. Clin Transl Sci. 2021. PMID: 33503289 Free PMC article. Clinical Trial.